Continuous ECG increases AF detection 10-folds compared to standard care: JAMA

Written By :  Medha Baranwal
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2021-03-10 04:30 GMT   |   Update On 2021-03-10 04:35 GMT

Canada: Screening atrial fibrillation (AF) with a wearable cECG monitor versus standard care increased AF detection 10-fold in older hypertension patients, show results from SCREEN-AF trial. Further, it also prompted initiation of anticoagulation in most cases. The findings of the study are published in the journal JAMA Cardiology.Atrial fibrillation is a major cause of strokes that can...

Login or Register to read the full article

Canada: Screening atrial fibrillation (AF) with a wearable cECG monitor versus standard care increased AF detection 10-fold in older hypertension patients, show results from SCREEN-AF trial. Further, it also prompted initiation of anticoagulation in most cases. 

The findings of the study are published in the journal JAMA Cardiology.

Atrial fibrillation is a major cause of strokes that can be prevented. Screening asymptomatic patients for AF may increase the use of anticoagulants for the prevention of stroke. David J. Gladstone, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada, and colleagues aimed to evaluate 2 home-based AF screening interventions.

For the purpose, the researchers performed a multicenter randomized clinical trial and recruited older patients (aged 75 years and above) with hypertension and without known AF from primary care practices. A total of 2019, 856 participants were enrolled between April 5, 2015, to March 26, 2019 from 48 practices.

The patients were divided into two groups -- control group received (routine clinical follow-up plus a pulse check and heart auscultation at baseline and 6 months) and screening group received a 2-week continuous electrocardiographic (cECG) patch monitor to wear at baseline and at 3 months, in addition to standard care. The screening group also received automated home blood pressure (BP) machines with oscillometric AF screening capability to use twice-daily during the cECG monitoring periods.

The primary outcome was AF detected by cECG monitoring or clinically within 6 months. 

Key findings of the study include:

  • In the primary analysis, AF was detected in 23 of 434 participants (5.3%) in the screening group vs 2 of 422 (0.5%) in the control group (relative risk, 11.2; number needed to screen, 21).
  • Of those with cECG-detected AF, median total time spent in AF was 6.3 hours (IQR, 4.2-14.0 hours; range 1.3 hours-28 days), and median duration of the longest AF episode was 5.7 hours (IQR, 2.9-12.9 hours).
  • Anticoagulation was initiated in 15 of 20 patients (75.0%) with cECG-detected AF. By 6 months, anticoagulant therapy had been prescribed for 18 of 434 participants (4.1%) in the screening group vs 4 of 422 (0.9%) in the control group (relative risk, 4.4).
  • Twice-daily AF screening using the home BP monitor had a sensitivity of 35.0%, specificity of 81.0%, positive predictive value of 8.9%, and negative predictive value of 95.9%.
  • Adverse skin reactions requiring premature discontinuation of cECG monitoring occurred in 5 of 434 participants (1.2%).

"Compared with regular checks in primary care, continuous ECG monitoring revealed more asymptomatic older people with hypertension as having atrial fibrillation (Afib)," concluded the authors.

"In this trial, a wearable electrocardiogram-based screening intervention increased atrial fibrillation detection 10-fold and prompted anticoagulation in most cases; this strategy warrants evaluation to prevent stroke," they wrote. 

The study titled, "Screening for Atrial Fibrillation in the Older Population: A Randomized Clinical Trial," is published in the journal JAMA Cardiology.

DOI: https://jamanetwork.com/journals/jamacardiology/article-abstract/2776728

Tags:    
Article Source : JAMA Cardiology

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News